Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 2965-2972

  Zonnenberg, Bernard A ^a   Groenewegen, Gerard ^a   Janus, Todd J ^b   Leahy, Terri W ^b   Humerickhouse, Rod A ^b   Isaacson, Jeffrey D ^b   Carr, Robert A ^b   Voest, Emile ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; ATRASENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; OXYMETAZOLINE; VERAPAMIL;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DYSPNEA; FACE EDEMA; FEMALE; HEADACHE; HEMATURIA; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RHINITIS; SUPRAVENTRICULAR TACHYCARDIA; TUMOR GROWTH; VASCULAR DISEASE; VASODILATATION; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; TIME FACTORS;

EID: 0041464540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond.), 332: 411-415, 1988.
2. Battistini, B., Chailler, P., D'Orleans-Juste, P., Briere, N., and Sirois, P. Growth regulatory properties of endothelins. Peptides, 14: 385-399, 1993.
3. Kozawa, O., Kawamura, H., Hatakeyama, D., Matsuno, H., and Uematsu, T. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase. Cell. Signalling, 12: 375-380, 2000.
4. Bagnato, A., Rosano, L., Di Castro, V., Albini, A., Salani, D., Varmi, M., Nicotra, M. R., and Natali, P. G. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am. J. Pathol., 158: 841-847, 2001.
5. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
6. Shichiri, M., Hirata, Y., Nakajima, T., Ando, K., Imai, T., Yanagisawa, M., Masaki, T., and Marumo, F. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J. Clin. Investig., 87: 1867-1871, 1991.
7. Bagnato, A., and Catt, K. J. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol. Metab., 9: 378-383, 1998.
8. Gray, G. A., and Webb, D. J. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol. Ther., 72: 109-148, 1996.
9. Bagnato, A., Tecce, R., Di Castro, V., and Catt, K. J. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res., 57: 1306-1311, 1997.
10. Nelson, J. B., Chan-Tack, K., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., and Simons, J. W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res., 56: 663-668, 1996.
11. Wu-Wong, J. R., and Opgenorth, T. J. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J., 328: 733-737, 1997.
12. Langenstroer, P., Tang, R., Shapiro, E., Divish, B., Opgenorth, T., and Lepor, H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol., 150: 495-499, 1993.
13. Casey, M. L., Byrd, W., and MacDonald, P. C. Massive amounts of immunoreactive endothelin in human seminal fluid. J. Clin. Endocrinol. Metab., 74: 223-225, 1992.
14. Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., and Simons, J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med., 1: 944-949, 1995.
15. Nelson, J. B., and Carducci, M. A. The role of the endothelin axis in prostate cancer. Prostate J., 1: 126-130, 1999.
16. Le Brun, G., Aubin, P., Soliman, H., Ropiquet, F., Villette, J. M., Berthon, P., Creminon, C., Cussenot, O., and Fiet, J. Upregulation of endothelin 1 and its precursor by 1L-1-β, TNF-α, and TGF-β in the PC3 human prostate cancer cell line. Cytokine, 11: 157-162, 1999.
17. Gohji, K., Kitazawa, S., Tamada, H., Katsuoka, Y., and Nakajima, M. Expression of endothelin receptor A associated with prostate cancer progression. J. Urol., 165: 1033-1036, 2001.
18. Bagnato, A., Salani, D., DiCastro, V., Wu-Wong, J. R., Tecce, R., Nicotra, M. R., Venuti, A., and Natali, P. G. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res., 59: 720-727, 1999.
19. Venuti, A., Rosano, L., Salani, D., Poggiali, F., Padley, R., and Bagnato. A. Endothelin A receptor antagonists: new potential anticancer therapy in HPV associated cervical carcinoma. Presented at the 18th International Conference on Papilloma Virus, Barcelona, Spain, July 23-28, 2000.
20. Venuti, A., Salani, D., Manni, V., Poggiali, F., and Bagnato, A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J., 14: 2277-2283, 2000.
21. Baley, P. A., Resink, T. J., Eppenberger, U., and Hahn, A. W. A. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells. J. Clin. Investig., 85: 1320-1323, 1990.
22. Yamashita, J., Ogawa, M., Egami, H., Matsuo, S., Kiyohara, H., Inada, K., Yamashita, S., and Fujita, S. Abundant expression of immunoreactive endothelin-1 in mammary phyllodes tumor: possible paracrine role of endothelin-1 in the growth of stromal cells in phyllodes tumor. Cancer Res., 52: 4046-4049, 1992.
23. Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., Novosad, E. I., Von Geldern, T. W., Wessale, J. L., Winn, M., and Wu-Wong, J. R. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther., 276: 473-481, 1996.
24. Wu-Wong, J. Endothelin receptor antagonists: past, present and future. Curr. Opin. Cardiovasc. Pulmon. Renal Invest. Drugs, 1: 346-351, 1999.
25. Bryan, P. D., Sapochak, L. B., Tarnes, M. M., Padley, R. J., and El-Shourbagy, T. A. Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma. Biomed. Chromatogr., 15: 1-9, 2001.
26. Verhaar, M. C., Grahn, A. Y., Van Weerdt, A. W., Honing, M. L., Morrison, P. J., Yang, Y. P., Padley, R. J., and Rabelink, T. J. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br. J. Clin. Pharmacol., 49: 562-573, 2000.
27. Carducci, M., Bowling, M., Rogers, T., Eisenberger, M., Sinibaldi, V., Donehower, R., Leahy, T., Carr, R., Isaacson, J., Janus, T., Andre, A., Hosmane, B., and Padley, R. Atrasentan (ABT-627), an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol., 20: 2171-2180, 2002.
28. Abbott Laboratories Study Report M96-435. A Phase I, Double-blind, Placebo-controlled Multiple Dose Study of the Safety and Tolerability of ABT-627. Abbott Park, IL: Abbott Laboratories, 1998.
29. Dingemanse, J., Clozel, M., and van Giersbergen, P. L. M. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br. J. Clin. Pharmacol., 53: 355-362, 2002.
30. Krum, H., Viskoper, R. J., Lacourciere, Y., Budde, M., and Charlon, V. The effect of an endothelin-receptor antagonist, Bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med., 338: 784-790, 1998.
31. Packer, M. Beta-blockage in heart failure: basic concepts and clinical results. Am. J. Hypertens., 11: 23S-37S, 1998.
32. Abraham, W. T., Ascheim, D., DeMarco, T., Klapholz, M., Kukin, M., Miller, A., Yellen, L., Holcslaw, T. L., Packer, M., and ENCOR Investigators. Effects of enrasentan, a nonselective endothelin receptor antagonist, in class II-III heart failure: results of the enrasentan cooperative randomized evaluation. Presented at the American College of Cardiology Meeting, 50th Scientific Session, Orlando, Florida, March 18-21, 2001.
33. Salani, D., Di Castro, V., Nicotra, M. R., Rosano, L., Tecce, R., Venuti, A., Natali, P. G., and Bagnato, A. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol., 157: 1537-1547, 2000.